Based on our integrated cohort and the TCGA LUAD cohort, we identified 28774 high-confidence alternative splicing events (ASEs), which affected 8726 genes, including targets for tyrosine kinase inhibitors used to treat lung cancer, such as EGFR, RET, and MET (see methods) (Fig. 1b). The gene discussed is EGFR; the disease is lung carcinoma.